Efficacy of cryotherapy for the treatment of cutaneous leishmaniasis: Meta-analyses of clinical trials

BMC Infectious Diseases

Volumn 16, Issue 1, 2016, Pages

  López Carvajal, Liliana ^a   Cardona Arias, Jaiberth Antonio ^a,b   Zapata Cardona, María Isabel ^a   Sánchez Giraldo, Vanesa ^a   Vélez, Iván Darío ^a  

^a UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^b UNIVERSIDAD COOPERATIVA DE COLOMBIA   (Colombia)

Author keywords

Clinical trials as a topic; Cryotherapy; Efficacy; Leishmaniasis, cutaneous; Meta analysis as a topic

Indexed keywords

MEGLUMINE ANTIMONATE; STIBOGLUCONATE SODIUM; ANTIPROTOZOAL AGENT;

AGE DISTRIBUTION; ARTICLE; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; CRYOTHERAPY; ERYTHEMA; EVIDENCE BASED MEDICINE; HUMAN; HYPERPIGMENTATION; HYPOPIGMENTATION; INTENTION TO TREAT ANALYSIS; META ANALYSIS; PAIN; POPULATION DISTRIBUTION; PRIMARY MEDICAL CARE; REPRODUCIBILITY; RISK FACTOR; SAFETY; SEX DIFFERENCE; SKIN EDEMA; SKIN LEISHMANIASIS; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; LEISHMANIASIS, CUTANEOUS; STATISTICAL MODEL;

ANTIPROTOZOAL AGENTS; CLINICAL TRIALS AS TOPIC; CRYOTHERAPY; HUMANS; LEISHMANIASIS, CUTANEOUS; MODELS, STATISTICAL; TREATMENT OUTCOME;

EID: 84979282907     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-016-1663-3     Document Type: Article

References (32)

1. Vélez ID, Hendrickx E, Robledo SM, Agudelo SP. Leishmaniosis cutánea en Colombia y género. Cad Saude Publica. 2001;17(1):171-80.
2. De Negri OGEJR, Flores M, Cuellar P, Caja Pulido T, Peñataro Yori P. Manual de Enfermedades Tropicales Desatendidas. Madrid, España: Fundación para el desarrollo de la Enfermería; 2010. p. 41-2.
3. Alvar JP. Las Leishmaniasis: de la Biología al control. 2nd ed. Madrid: Laboratorios Intervet S.A; 2001. p. 70-1.
4. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012;7(5):e35671.
5. Dobles-Ulloa A, Perriard C. Representaciones, actitudes y prácticas respecto a la Leishmaniasis Cutánea en la población del Cantón de Acosta, provincia de San José, Costa Rica: estudio antropológico exploratório. Cad Saude Publica. 1994;10(2):181-9.
6. Alvar J, Yactayo S, Bern C. Leishmaniasis and poverty. Trends Parasitol. 2006;22(12):552-7.
7. Ministerio de la protección social. Guía para la Atención Clínica Integral del Paciente con Leishmaniasis. Bogotá: Ministerio de la Protección Social; 2010.
8. Barberis F, Vélez ID. Opciones Terapéuticas para el manejo de la Leishmaniais cutánea Americana. Rev Panam Infectol. 2014;16(2):113-22.
9. Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet. 2005;366(9496):1561-77.
10. Layegh P, Pezeshkpoor F, Soruri AH, Naviafar P, Moghiman T. Efficacy of Cryotherapy versus Intralesional Meglumine Antimoniate (Glucantime) for Treatment of Cutaneous Leishmaniasis in Children. Am J Trop Med Hyg. 2009;80(2):172-5.
11. Wein AKL, Novick A, Partin A, Peters G. Urología. Novena Edición. Madrid: Editorial Médica Panamericana S.A; 2008. p. 3035-9.
12. Panagiotopoulos A, Stavropoulos PG, Hasapi V, Papakonstantinou A-M, Petridis A, Katsambas A. Treatment of cutaneous leishmaniasis with cryosurgery. Int J Dermatol. 2005;44(9):749-52.
13. Soto J, Rojas E, Guzman M, Verduguez A, Nena W, Maldonado M, et al. Intralesional antimony for single lesions of bolivian cutaneous leishmaniasis. Clin Infect Dis. 2013;56(9):1255-60.
14. Negera E, Gadisa E, Hussein J, Engers H, Kuru T, Gedamu L, et al. Treatment response of cutaneous leishmaniasis due to Leishmania aethiopica to cryotherapy and generic sodium stibogluconate from patients in Silti, Ethiopia. Trans Royal Soc of Trop Med and Hyg. 2012;106(8):496-503.
15. Salmanpour R, Razmavar MR, Abtahi N. Comparison of intralesional meglumine antimoniate, cryotherapy and their combination in the treatment of cutaneous leishmaniasis. Int J Dermatol. 2006;45(9):1115-6.
16. Martínez FM, Meca JS, López JL. El metaanálisis en el ámbito de las Ciencias de la Salud: una metodología imprescindible para la eficiente acumulación del conocimiento. Fisioterapia. 2009;31(3):107-14.
17. Organización Panamericana de la Salud OPS. Leishmaniasis en las américas: Recomendaciones para el tratamiento. Washington: OPS; 2013.
18. Urrútia G, Declaración BX, PRISMA. Una propuesta para mejorar la publicación de revisiones sistemáticas y metaanálisis. Med Clin. 2010;135(11):507-11.
19. Özgöztaslis O, Kirtak N, Erbagčci Z. Cryotherapy in the treatment of cutaneous leishmaniasis. J Dermatolog Treat. 1997;8(3):179-82. 19.
20. López-Jaramillo P, Rincón MY, García RG, Silva SY, Smith E, Kampeerapappun P, et al. A controlled, randomized-blinded clinical trial to assess the efficacy of a nitric oxide releasing patch in the treatment of cutaneous leishmaniasis by Leishmania (V.) panamensis. Am J Trop Med Hyg. 2010;83(1):97.
21. Asilian A, Sadeghinia A, Faghihi G, Momeni A. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime®) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime®) alone for the treatment of cutaneous leishmaniasis. Int J Dermatol. 2004;43(4):281-3.
22. Gurei MS, Tatli N, Ozbilge H, Erel O, Seyrek A, Kocyigit A, et al. Efficacy of cryotherapy and intralesional pentostam in treatment of cutaneous leishmaniasis. J Egypt Soc Parasitol. 2000;30(1):169-76.
23. Velásquez OH. Caracterización clínica y epidemiológica de la enfermedad Leishmaniasis cutánea en el Área Norte del departamento de Peten. Guatemala: Universidad de San Carlos de Guatemala; 2010.
24. Lin H-P, Chen H-M, Cheng S-J, Yu C-H, Chiang C-P. Cryogun cryotherapy for oral leukoplakia. Head Neck. 2012;34(9):1306-11.
25. Mosleh IM, Geith E, Natsheh L, Schönian G, Abotteen N, Kharabsheh S. Efficacy of a weekly cryotherapy regimen to treat Leishmania major cutaneous leishmaniasis. J Am Acad Dermatol. 2008;58(4):617-24.
26. Bassiouny A, El Meshad M, Talaat M, Kutty K, Metawaa B. Cryosurgery in cutaneous leishmaniasis. Br J Dermatol. 1982;107(4):467-74.
27. Shirian S, Oryan A, Hatam GR, Daneshbod Y. Three Leishmania/L. species - L. infantum, L. major, L. tropica - as causative agents of mucosal leishmaniasis in Iran. Pathog Glob Health. 2013;107(5):267-72.
28. García-Almagro D. Leishmaniasis cutánea. Actas Dermosifiliogr. 2005;96(1):1-24.
29. Giudice A, Camada I, Leopoldo PT, Pereira JM, Riley LW, Wilson ME, et al. Resistance of Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis to nitric oxide correlates with disease severity in Tegumentary Leishmaniasis. BMC Infect Dis. 2007;7(1):7.
30. el Darouti MA, al Rubaie SM. Cutaneous leishmaniasis. Treatment with combined cryotherapy and intralesional stibogluconate injection. Int J Dermatol. 1990;29(1):56-9.
31. Al-Mutairi N, Alshiltawy M, Khalawany ME, Joshi A, Eassa BI, Manchanda Y, et al. Treatment of Old World cutaneous leishmaniasis with dapsone, itraconazole, cryotherapy, and imiquimod, alone and in combination. Int J Dermatol. 2009;48(8):862-9.
32. Brooks DCC, Frenette J, Lam T, Mackay-Lyons M. Electrophysical agents: Contraindications and precautions. Canadá: Physiotherapy. Canada; 2010.